Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
Meletios Α. Dimopoulos(Korea University), Shaji Kumar(Mayo Clinic), Yolanda González Montes(Hospital Universitari de Girona Doctor Josep Trueta), Hélène Demarquette(Ikerbasque), Cindy Lee(University of Toronto), Olga Vinogradova(City Clinical Hospital), Xavier Leleu(Inserm), Alexander Vorog(Takeda (United States)), Alessandra Pompa(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Fredrik Schjesvold(Oslo University Hospital), Vadim Doronin(City Clinical Hospital), Roland Fenk(Beth Israel Deaconess Medical Center), Hang Quach(The University of Melbourne), Richard Labotka(Takeda (United States)), Hamdi Sati(Swansea Bay University Health Board), Jichang Du(Takeda (United States)), Mark‐David Levin(Albert Schweitzer Hospital), Ulf Henrik Mellqvist(Södra Älvsborg Hospital), Mohamed Darif(Biogen (United States))
Cited by 21
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k